[Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
To evaluate the efficacy of accelerated hyperfractionation (CAF) radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer. Between June 2004 and January 2008, 53 patients with locoregional recurrent rectal cancer were treated with CAF 1.2 Gy/f, 2 f/d plus concurrent capecitabine at an oral dosage of 825 mg/m2 bid on each day of radiotherapy period. The first daily dose was applied at 2 h pre-irradiation, d1-14 and d22-35. After a regimen of 36 Gy/30 f/3 w, the feasibility of surgical resection was then evaluated by CT. Patients unsuitable for surgical resection continued CAF. And the total dose was 52.8-57.6 Gy. The complete response rate was 9.8%, the partial response rate 45.1%, the effective rate 54.9%, the no-change rate 29.4%, the progression rate 15.7%, the surgical resection rate 23.5% and the R0, R1 resection rates 21.6% and 1.9% respectively. The Time to Progression was 10.5 months, 1-year survival rate was 84.3%, 2-year survival rate was 61.1%. Quality of life improved in treatment group. Toxic and adverse effects were gastrointestinal and hematological toxicities. There was no treatment-related mortality. The 3-dimensional conformal radiotherapy plus concurrent chemotherapy may be an effective and well-tolerated regimen in patients with postoperative locoregional recurrent or metastatic rectal cancer.